Alseres Pharmaceuticals Inc (ALSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2004 | 03-2004 | 12-2003 | 09-2003 | 06-2003 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,086 | 1,391 | 6,089 | 1,597 | 1,322 |
| Marketable Securities | 8,763 | 7,691 | 5,322 | 9,215 | 11,127 |
| Other current assets | 459 | 844 | 0 | 415 | 562 |
| TOTAL | $10,309 | $9,926 | $11,927 | $11,227 | $13,011 |
| Non-Current Assets | |||||
| PPE Net | 495 | 552 | 605 | 659 | 714 |
| Investments And Advances | 0 | 4,590 | 0 | 0 | 0 |
| Other Non-Current Assets | 392 | 303 | 4,902 | 319 | 327 |
| TOTAL | $887 | $5,445 | $5,506 | $978 | $1,041 |
| Total Assets | $11,196 | $15,371 | $17,433 | $12,205 | $14,051 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,989 | 2,189 | 1,506 | 1,442 | 1,356 |
| TOTAL | $5,983 | $6,091 | $5,317 | $5,380 | $5,235 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $5,983 | $6,091 | $5,317 | $5,380 | $5,235 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1 | 1 | 1 | 1 | 1 |
| Common Shares | 342 | 340 | 65 | 325 | 325 |
| Retained earnings | -101,146 | -97,118 | -94,396 | -92,301 | -90,283 |
| Other shareholders' equity | -25 | 23 | 1 | -58 | -64 |
| TOTAL | $5,213 | $9,280 | $12,116 | $6,826 | $8,817 |
| Total Liabilities And Equity | $11,196 | $15,371 | $17,433 | $12,205 | $14,051 |